These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Strengths of Total Holographic Video Microscopy in Detecting Sub-Visible Protein Particles in Biopharmaceuticals: A Comparison to Flow Imaging and Resonant Mass Measurement. Rahn H; Oeztuerk M; Hentze N; Junge F; Hollmann M J Pharm Sci; 2023 Apr; 112(4):985-990. PubMed ID: 36596393 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of subvisible particles in human immunoglobulin and lipid nanoparticles repackaged from a multi-dose vial using plastic syringes. Hada S; Na KJ; Jeong J; Choi DH; Kim NA; Jeong SH Int J Biol Macromol; 2023 Mar; 232():123439. PubMed ID: 36716845 [TBL] [Abstract][Full Text] [Related]
27. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions. Barnard JG; Rhyner MN; Carpenter JF J Pharm Sci; 2012 Jan; 101(1):140-53. PubMed ID: 22109687 [TBL] [Abstract][Full Text] [Related]
28. Rapid Quantification of Protein Particles in High-Concentration Antibody Formulations. Wu H; Randolph TW J Pharm Sci; 2019 Mar; 108(3):1110-1116. PubMed ID: 30773198 [TBL] [Abstract][Full Text] [Related]
29. A critical review of analytical methods for subvisible and visible particles. Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412 [TBL] [Abstract][Full Text] [Related]
30. Quantitative laser diffraction method for the assessment of protein subvisible particles. Totoki S; Yamamoto G; Tsumoto K; Uchiyama S; Fukui K J Pharm Sci; 2015 Feb; 104(2):618-26. PubMed ID: 25449441 [TBL] [Abstract][Full Text] [Related]
31. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress. Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805 [TBL] [Abstract][Full Text] [Related]
32. Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis. Zhang K; Wrzosek T; Desai KG; Monck M PDA J Pharm Sci Technol; 2020; 74(1):15-26. PubMed ID: 31519785 [TBL] [Abstract][Full Text] [Related]
33. Unmasking translucent protein particles by improved micro-flow imaging™ algorithms. Pedersen JS; Persson M J Pharm Sci; 2014 Jan; 103(1):107-14. PubMed ID: 24281987 [TBL] [Abstract][Full Text] [Related]
34. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience. Gervais D; Corn T; Downer A; Smith S; Jennings A AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894 [TBL] [Abstract][Full Text] [Related]
38. Recent Achievements and Current Interests in Research on the Characterization and Quality Control of Biopharmaceuticals in Japan. Ishii-Watabe A; Shibata H; Suetomo H; Ikeda Y; Telikepalli S; Kiyoshi M; Hayashi Y; Muto T; Tanaka Y; Ueda S; Iwura T; Saitoh S; Aoyama M; Harazono A; Hyuga M; Goda Y; Torisu T; Uchiyama S J Pharm Sci; 2020 May; 109(5):1652-1661. PubMed ID: 31927040 [TBL] [Abstract][Full Text] [Related]
39. Correcting the Relative Bias of Light Obscuration and Flow Imaging Particle Counters. Ripple DC; Hu Z Pharm Res; 2016 Mar; 33(3):653-72. PubMed ID: 26555667 [TBL] [Abstract][Full Text] [Related]
40. Convolutional Neural Networks Enable Highly Accurate and Automated Subvisible Particulate Classification of Biopharmaceuticals. Wang S; Liaw A; Chen YM; Su Y; Skomski D Pharm Res; 2023 Jun; 40(6):1447-1457. PubMed ID: 36471026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]